Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Phase 1 Terminated 16 enrolled Dana-Farber Cancer Institute AstraZeneca · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: * Durvalumab * Tremelimumab

Timeline

Start: 2018-06-01
Primary completion: 2022-07-15
Completion: 2022-07-15

Publications

Fitzgerald KJ, Konstantinopoulos P, Matulonis U, Liu J, Horowitz N, Lee E, Kolin DL, Lee L, King M. A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer. Gynecol Oncol. 2025 Jun;197:51-56. doi: 10.1016/j.ygyno.2025.04.006. Epub 2025 Apr 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Durvalumab	Monoclonal antibody	1500 mg	Intravenous
Subject	Tremelimumab	Monoclonal antibody	75 mg	Intravenous

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Summary

Timeline

Publications

Drugs

Indications